CAILIN addresses these questions through training on COTA's proprietary datasets while guided by in-house oncology expertise. CAILIN expedites access to data and oncology-specific insights across the pharmaceutical R&D life cycle and, in the near future, will provide additional ways to develop hypotheses and generate evidence.
